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Abstract
Respiratory physiotherapy is part of the routine management of patients with cystic
fibrosis. It normally consists of airway clearance techniques and exercise training. The
evidence of such interventions has been questioned. Nevertheless, the lack of evidence
should not be interpreted as lack of benefit. Instead, attention to methodological
issues, such as the selection of the outcome measures, is needed, as they may hamper
the establishment of the effectiveness of respiratory physiotherapy techniques. Hence,
this chapter presents and discusses the strengths and weaknesses of conventional and
emerging outcome measures possibly to be used (i) in clinical practice before, during
and after each session of respiratory physiotherapy to monitor its effectiveness; (ii)
before and after the respiratory physiotherapy treatment (i.e., normally characterised
by weeks of intervention) and (iii) in applied research in respiratory physiotherapy
used in the management for cystic fibrosis. A comprehensive overview of the available
outcome measures is provided, with particular emphasis on their strengths and
limitations that should be recognised when interpreting the results.
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1. Introduction
Respiratory physiotherapy is a non-pharmacological treatment commonly provided to
patients with cystic fibrosis (CF) [1]. According to international guidelines, respiratory
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physiotherapy is a key element of care for patients with CF, as it aims at both rehabilitation
and prevention [2]. Specifically, respiratory physiotherapy is used to deal with the progressive
loss of pulmonary function accompanied by symptoms of cough, excessive sputum produc‐
tion, dyspnoea, exercise intolerance, reduced functionality and impaired quality of life. To
respond to these multiple problems and needs, respiratory physiotherapy involves a range of
strategies and techniques, such as airway clearance, exercise training and breathlessness
management, which have an overall aim of reducing the progression of the disease [3, 4].
However, there is a lack of evidence to suggest the superiority of one technique over the other
[5] and to determine which strategies promote the adherence of this population to regular
physical activity [6]. Nevertheless, the lack of evidence does not mean lack of benefit. Instead,
methodological issues, such as the selection of the outcome measures, may hamper the
establishment of the effectiveness of the respiratory physiotherapy techniques.
Respiratory physiotherapists use several outcome measures to monitor and evaluate their
interventions. Most of the clinically available outcome measures are not specific for the
physiotherapy intervention employed and may be affected by other factors. This means that
there are no gold standard outcome measures specifically related to respiratory physiotherapy
interventions. Thus, in all areas of respiratory physiotherapy, one of the barriers to generate
evidence has been the lack of accurate, reliable, sensitive and valid outcome measures. To
overcome this problematic issue, new measures have been emerging.
This chapter starts by providing an overview of the problem. It then presents and discusses
the strengths and weaknesses of the commonly used clinical outcome measures and other
measures that have been gaining interest in the assessment and monitoring of respiratory
physiotherapy interventions in CF. The chapter ends with a brief conclusion. A comprehensive
overview of the available outcome measures is sought to be provided, with particular emphasis
on their strengths and limitations that should be recognised when interpreting the results.
2. Outcome measures for respiratory physiotherapy
Respiratory physiotherapy in CF involves a wide range of interventions and among them
airway clearance techniques and exercise training are recognised as the most important. The
primary aim of airway clearance techniques is to relieve the airway obstruction by promoting
the normal mucociliary clearance mechanism of the lungs and facilitating expectoration, thus
reducing the risk of infection and inflammation. A variety of airway clearance techniques have
been developed. Some involve airway oscillation, some are independently performed and
others require electricity or physical assistance [5]. Exercise training is advocated as an
important package of care delivered to patients with CF [5], since exercise intolerance has been
associated with reduced survival [45]. Observed benefits of exercise training include slow
pulmonary function decline [46], reduced dyspnoea and improved exercise capacity, muscle
strength and health-related quality of life (HRQoL) [47].
Although adhering to airway clearance techniques [7] and exercise training is generally
regarded as beneficial for patients with CF, there is no consensus about the superiority of one
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technique over the other [5]. Methodological issues, such as the underpowered samples or the
selection of the outcome measures, may explain this lack of evidence and thus hamper the
establishment of the effectiveness of these interventions. A clear example of this issue has been
the use of forced expiratory volume in the first second (FEV1) as a gold standard to assess the
impact of the mentioned interventions for many years, which is currently considered as not a
sensitive measure to be used in respiratory physiotherapy [5].
Most of the clinically available outcome measures are not specifically related to the physio‐
therapy intervention employed and may be affected by other factors. This means that there is
no gold standard outcome measure that is specifically related to respiratory physiotherapy
interventions. Moreover, there are many doubts about the accuracy, reliability, sensitivity and
validity of the current measures. Given this problematic situation, several researchers have
been investigating the potential of other objective, simple and non-invasive measures to be
used as outcome measures in respiratory physiotherapy.
The outcome measures most commonly used by respiratory physiotherapists to monitor their
interventions and evaluate their practice are: FEV1, respiratory sounds, sputum weight,
measures of oxygenation, chest radiography, dyspnoea, exercise capacity and HRQoL.
Computerised respiratory sounds, lung ultrasound, fat-free mass, inspiratory muscle strength
and endurance, physical activity and burden of treatment are some examples of these emerging
outcome measures to assess and monitor respiratory physiotherapy interventions in CF. Each
one of these outcome measures, their strengths and weaknesses are presented in detail below
according to their novelty in the field (i.e., conventional and emerging).
2.1. Conventional outcome measures
2.1.1. Forced expiratory volume in the first second
The most common pulmonary function test performed to assess respiratory physiotherapy
interventions is the forced spirometry, i.e., the volume and/or flow of air that can be inhaled
and exhaled as a function of time. The procedure consists in three distinct phases: (1) maximal
inspiration followed by an expiration at functional residual capacity; (2) a ‘‘blast’’ of exhalation;
and (3) continued complete exhalation until the end of test [8]. First, the patient should exhale
until he or she reaches the functional residual capacity and then be instructed to inhale rapidly
and completely. In this phase, the mouthpiece should be placed in the patient’s mouth and
indications should be given for the patient to blow as much and as fast as possible and to keep
blowing until totally emptying the lungs. Spirometry has been described as a cost-effective,
simple, reliable, valid and easy-to-interpret bedside measure [8]. The most used pulmonary
function parameter is the forced expiratory volume in the first second (FEV1), followed by the
forced vital capacity (FVC) and the ratio between FEV1/FVC. Measurements are taken
considering patient’s gender, age, height, weight and race and are then compared with
predicted values.
Spirometry, namely FEV1, has been used to assess the effectiveness of respiratory physiother‐
apy interventions. However, contradictory findings have emerged. Pfleger et al. (1992) found
significant improvements in FEV1 after autogenic drainage and high-pressure PEP-mask (n=14,
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Cohen’s dz 0.09 and 0.22) [9]. Jarad, Powell and Smith (2010) reported a statistically significant
reduction in FEV1 following hydro-acoustic therapy (n=19, Cohen’s dz=0.12) or flutter (n=19,
Cohen’s dz=0.06) [10]. Nevertheless, these changes returned to baseline on the second study
day [10].
In two recent reviews where conventional physiotherapy [11] and the active cycle of breathing
techniques (ACBT) [12] were compared with other airway clearance techniques, no significant
differences were observed between the techniques in terms of pulmonary function measured
with spirometry [11]. Nevertheless, when oscillating devices for airway clearance were used,
significant results were observed in pulmonary function, the FEV1 being the primary outcome
measure more frequently reported [13].
Findings in the literature about the effectiveness of respiratory physiotherapy interventions
in CF remain controversial when FEV1 is considered as the outcome measure. This is in part
due to the fact that accuracy and sensitivity of spirometry depends on many factors that are
difficult to control and not related to the intervention itself. Some examples of these factors are
the transducer characteristics, presence or absence of an in-line filter, presence or absence of a
display, patient’s mood and motivation to cooperate, relationship between the patient and the
technician, among others. Therefore, spirometry might be unsuitable or its reliability may be
affected in a number of situations, for example if the equipment or settings change, if patients
are unwilling or unable to collaborate (e.g. children, people with dementia), or if pain or
discomfort is present. Hence, this measure should be routinely used to characterise the
pulmonary function of patients with CF, but not to assess the effectiveness of respiratory
physiotherapy interventions.
2.1.2. Respiratory sounds
Lung auscultation, performed with conventional stethoscopes, is one of the oldest and most
used techniques to diagnose and monitor respiratory diseases [14, 15]. It consists in acquiring
acoustic signals from the lung structures during spontaneous or controlled volume or flow
breathing, and classifying the respiratory sounds as normal or abnormal (e.g., adventitious
respiratory sounds, such as crackles and wheezes) [15]. Auscultation is recognised as an
efficient and safe method for the early detection of respiratory diseases as it is non-invasive,
practical, low cost and easy to apply in all clinical settings and patients, irrespective of patients’
age and severity of the disease [14-16].
The efficiency of this method depends on the hearing ability of the health professionals [17],
their capacity to memorise different sound patterns [18] and on the quality of the acoustic
properties of the stethoscope being used [17]. Considering these limitations and subjectivity,
reliability studies have been performed. In CF there are no reliability studies using conven‐
tional stethoscopes. However, in other respiratory diseases, poor to fair correlations between
different raters have been reported, either in taped recorded sounds (kappa=0.26 and coeffi‐
cient of reliability of less than 60%) [19, 20] and real-time auscultation (–0.02<kappa<0.77) [21].
Using digital stethoscopes, one study conducted in adult patients with CF assessed the inter-
rater agreement between real-time manual annotation of respiratory sounds and automatic
detection of respiratory sounds through a computerised system [22]. Poor to moderate
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correlations were found (–0.20<kappa<0.60) [22]. Similar results were found in children with
respiratory diseases (–0.08<kappa<0.86) [23–25]. Direct comparisons between conventional
and digital stethoscopes showed that, although digital stethoscopes have a better sound
quality [26], the performance of health professionals to detect respiratory sounds is not
enhanced by its use [27].
It is also important to note that, in all the studies, the recognition of crackles was always less
accurate than the recognition of wheezes. As respiratory sounds in CF are mainly characterised
by the presence of crackles [28] and conventional auscultation has provided poor reliability
results, particularly for detection of crackles, it can be concluded that respiratory sounds are
not a reliable outcome measure for CF diagnosis and monitoring. Also due to its poor relia‐
bility, conventional auscultation has not been used as an outcome measure for respiratory
physiotherapy interventions in recent research [7]. Nevertheless, due to its simplicity and wide
availability in all clinical settings, it is still recurrently used in clinical practice by physiothera‐
pists to monitor patients with CF and to define therapeutic approaches [3]. Despite these
limitations, the advantages of using lung auscultation should not be overlooked, and currently
significant research efforts are being conducted to create equipment capable of overcoming
the subjectivity associated with conventional auscultation while preserving its main advan‐
tages (i.e., portability, patients’ minimal cooperation and cost-effectiveness) [16].
2.1.3. Sputum weight
Mucus is transported from the bronchial airways towards the exterior by mucociliary clear‐
ance, spontaneous cough and through a range of airway clearance techniques, such as directed
huffs and coughs. Subsequently, secretions are either expectorated or swallowed. During
respiratory physiotherapy sessions, patients are encouraged to expectorate to a cup. Sputum
volume or weight can then be used as an outcome measure for respiratory physiotherapy.
While sputum volume has shown to be difficult to determine with precision, sputum weight
(either dry or wet) has shown to be more accurate [29]. In a recent Cochrane review on the
effectiveness of respiratory physiotherapy interventions in respiratory diseases, five of the
eight studies used sputum weight as an outcome measure, out of which four were conducted
in patients with CF [7]. Mortensen et al. (1991) found that patients expectorated 8–8.6g of
sputum weight after airway clearance techniques and 0 g during a control day (range 0–2.1 g)
[30]. In Pfeger et al. (1992), the mean weight of expectorated mucus with spontaneous cough
was approximately 17g whereas with airway clearance techniques ranged from 34 to 45g (n=14)
[9]. Although no mean and standard deviation was provided, Rossman et al. (1982) also found
a higher volume of expectorated secretions during the different forms of chest physiotherapy
compared to a control session (n=6) [31]. However, Jarad et al. (2010) found no significant
differences in wet or dry sputum weight between a positive expiratory pressure (PEP) device
(flutter) or a placebo [10].
Another study conducted by Osman et al. (2010) compared high-frequency chest wall
oscillation with conventional airway clearance techniques in 29 patients with CF using wet
sputum weight. Expectorated sputum in a single session was significantly different between
the techniques (p<0.001; Cohen’s dz=0.72) [32].
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The problem with sputum weight remains that the lack of expectoration during respiratory
physiotherapy techniques does not mean that airway clearance techniques are not effective. It
is very common to expectorate after respiratory physiotherapy sessions or to swallow
secretions even during the session, which means that sputum weight expectorated during a
session may underestimate the effect of airway clearance techniques. On the other hand,
expectoration may be contaminated with saliva [30]. Sputum weight can, therefore, be both
over- and under-estimated and it is not surprising that contradictory findings have been found
in the literature.
Although simple to collect and measure, sputum collected during and following the treatments
is not considered a reliable measure of alveolar recruitment, airway clearance or even sensitive
to small changes. In fact, this outcome measure has been frequently questioned [29, 30, 33–35]
and is no longer considered as a valid outcome measure for studies in airway clearance
techniques [36].
2.1.4. Measures of oxygenation
Blood gas measurements are used to evaluate a person's lung function and acid–base balance,
i.e., it measures the amount of oxygen and carbon dioxide that is in the blood and determines
its levels of acidity (pH). The test results provide information about the partial pressure of
oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) and hydrogen ion activity (pH) in
arterial blood, as well as indices of bicarbonate concentration, base excess and oxygen
saturation. The analysis is performed on the blood collected from a person’s artery and is
therefore, an invasive and relatively complex procedure. Although it is possible to measure
oxygenation more accurately, given the nature of the procedure, it is not practical to be
performed on a routine basis to monitor respiratory physiotherapy treatments. Hence,
transcutaneous pulse oximetry (reported as the percentage of saturation of arterial haemoglo‐
bin by oxygen [SaO2]) has become the most common method in clinical practice and research
for measuring oxygenation [37].
Peripheral oxygen saturation is commonly used as it is simple to perform via pulse oximeters
and finger probes. Pulse oximeters monitor the saturation of haemoglobin with oxygen (i.e.,
oxyhaemoglobin). This is possible because blood changes its colour as haemoglobin absorbs
various amounts of light depending on its saturation with oxygen. Oxyhaemoglobin absorbs
greater amounts of infrared light and does not absorb much red light, but as the haemoglobin
oxygen saturation drops, more and more red light is absorbed and the blood becomes darker.
Hence, pulse oximeters emit two wavelengths of light, red at 660 nm and near-infrared at 940
nm from the finger probe [38]. The pulse oximeter directly senses the absorption of light and
translates it through complex signal processing to a function of the arterial oxygen saturation.
A microprocessor integrates the data and, through an elaborate calibration algorithm based
on human volunteer data, the oxygen saturation can be estimated. This measure allows
constant monitoring of heart rate as well, being ideal to monitor patient’s safety during
interventions.
Nonetheless, this measure can provide unreliable readings due to several factors such as
haemoglobin level, arterial blood flow to the vascular bed, oximetry sensor location and
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temperature, fluorescent or direct sunlight, jaundice, discoloration of the nail bed, nail polish,
bruising under the nail, motion artefacts, intravascular dyes and skin pigmentation. All these
are discussed in detail elsewhere [38].
In two Cochrane reviews about respiratory physiotherapy techniques, insufficient evidence
was found regarding peripheral oxygen saturation as an outcome measure [7,12]. Osman et
al. (2010) compared high-frequency chest wall oscillation with conventional airway clearance
techniques in 29 patients with CF. It was found that, compared to the baseline, non-significant
changes in peripheral oxygen saturation were observed during or after any of the treatments
applied (Cohen’s dz from 0 to 0.28) [32]. However, in a recent study, the addition of non-
invasive ventilation to chest physiotherapy resulted in a significant reduction in the proportion
of treatment time with peripheral oxygen saturation below 90% (p<0.001) [39].
Controversial evidence exists on the potential of peripheral oxygen saturation as an adequate
measure to assess the effectiveness of respiratory physiotherapy. Hence, this measure seems
ideal to monitor patients’ safety but it may not present the required specificity and/or sensi‐
tivity to assess changes caused by respiratory physiotherapy interventions.
2.1.5. Dyspnoea
Dyspnoea is defined as “a subjective experience of breathing discomfort that consists of
qualitatively distinct sensations that vary in intensity” [40]. In a study conducted with 123
patients with CF, dyspnoea was reported to be present in 74% of the patients [41] and therefore,
it is an important problem to consider in this population. As a subjective experience, adequate
assessment depends on patient self-report. Depending on the circumstances in which breath‐
ing discomfort occurs and the history of similar sensations, dyspnoea may be perceived as a
threat associated with anxiety, fear or depression, and it may be viewed as a sign of disease.
This symptom has multidimensional aspects involving physiological, psychological, social
and environmental factors that result in a behavioural response. The assessment of multidi‐
mensional aspects of dyspnoea has assumed significance in recent years [40].
Dyspnoea has been assessed using scales and questionnaires, however, important differences
exists between these instruments, particularly in what they measure (e.g., one instrument may
ask what breathing feels like, whereas another may ask how distressing it is or how it impacts
on patient’s performance or quality of life), in the rating task (i.e., what patients are instructed
to rate), and in whether measurements are performed on real time or involve the recall of a
specific episode. These differences make comparisons across studies difficult.
In one study exploring the effectiveness of non-invasive ventilation during chest physiother‐
apy [39], it was found that dyspnoea scores, assessed with the Borg scale, increased in slightly
lesser extent following chest physiotherapy assisted with non-invasive ventilation than chest
physiotherapy alone (2.26±1.96 vs. 2.69±1.82, p=0.02, Cohen’s dz=0.23). Marques (2008),
however, found that dyspnoea assessed with the modified Borg scale was not significantly
different after one session of airway clearance techniques (Cohen’s dz=0.06) [42]. Enright et al.
(2004) investigated the effect of an 8-week inspiratory muscle training (n=19) and also did not
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find significant differences is dyspnoea, using the dyspnoea domain of the Chronic Respiratory
Disease Questionnaire (Cohen’s dz 0.07 to 0.37) [43].
A combination of unidimensional and multidimensional tools will probably be the best
approach for clinical assessment. Measurement of dyspnoea has to be seen in context, taking
into consideration the patient’s history, physical examination and diagnostic tests [44]. As
dyspnoea is a symptom perceived by patients, it has the potential to contribute for early
management of the disease, for adjusting the respiratory physiotherapy interventions and,
thus, for improving outcomes in patients.
2.1.6. Chest radiography
Several imaging techniques are available to diagnose and monitor a respiratory condition.
Within the respiratory field, chest radiography is the most commonly used. Although
relatively simple to perform, and in itself being relevant and reliable, the measure presents
several important limitations to be used as an outcome measure for respiratory physiotherapy.
The interpretation of chest radiography imaging is somewhat complex and presents high levels
of inter-observer subjectivity [45], the reports detailing either the presence or the absence of
any abnormalities are not commonly available immediately after the exam, its portability is
limited to places where health and safety radiation protection standards can be ensured, as
considerable doses of radiation are involved and is difficult to perform in non-collaborative
populations such as children or people with dementia. These factors prevent the use of this
measure to monitor respiratory physiotherapy patients with the required frequency.
In two long-term studies (n=36 and n=32), conducted for approximately one year comparing
different respiratory physiotherapy airways clearance techniques in patients with CF, chest
radiography was used as an outcome measure. However, no significant differences were
shown between interventions [46, 47]. In the most recent Cochrane reviews [11, 12] about
physiotherapy in CF, chest radiography is no longer reported as an outcome measure in the
included studies.
It therefore, seems that chest radiography is ideal for contributing to diagnosis and providing
a measure of improvement or deterioration over time but might not be the most appropriate
to be used as an outcome measure for respiratory physiotherapy.
2.1.7. Exercise capacity
The assessment of exercise capacity, expressed as the maximal workload achievable or the
peak oxygen consumption on a progressive maximal test, has been used to measure patients’
functional capacity and limitation, facilitates a safe exercise prescription and identifies changes
in patients’ performance as a result of an intervention [48, 49]. There are two types of clinically
applicable tests to assess exercise capacity in patients with CF: laboratory-based tests and field
tests [50, 51].
Laboratory-based tests, such as the cardiopulmonary exercise testing (CPET) [48, 49], are the
gold standard for evaluating the causes of exercise intolerance in patients with respiratory
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diseases, as they provide a comprehensive assessment of the physiological responses to
exercise involving the respiratory, cardiovascular and musculoskeletal systems [52]. CPET
consists of a progressive exercise performed at increasing levels of intensity either on a
treadmill or cycle ergometer, with simultaneous monitoring of breath-by-breath measures of
airflow (e.g., VO2, VCO2) along with heart rate, peripheral oxygen saturation and exercise-
related symptom responses (e.g. dyspnoea, leg discomfort) [49]. There are a number of
protocols that can be used to perform a CPET in patients with CF, but the most commonly
reported is the Godfrey protocol [53]. The CPET has been shown to be reproducible in young
and adult patients with CF [54, 55]. In patients with CF (n=23) enrolled in a strength and
endurance training for 6 months, significant differences were observed in VO2 peak between
3 and 6 months (Cohen’s dz=2.01) and between 18 and 24 months (Cohen’s dz=2.22) [56]. Despite
its sensitivity to change, the application of CPET is still limited in clinical settings [57]. This
may be attributable to the need for expensive equipment and technical expertise. For this
reason, field tests are more commonly used by physiotherapists to assess changes in exercise
capacity [58].
Field tests are simple clinical exercise tests that do not require expensive equipment [59] and,
thus, are suitable to be used at different settings of respiratory physiotherapy practice, such
as hospitals, private practices, at home or in community environments. In patients with CF,
the field tests most frequently used are the 6-minute walk test (6MWT), the 3-min step test
(3MST) and the modified shuttle test (MST) [51, 58]. The 6MWT measures the maximal distance
that a patient can walk in 6 minutes over a marked course (usually a corridor) following a
standardised protocol [60]. The 6MWT has been recommended for patients with CF [60] and
is valid and reliable for assessing exercise capacity in children [61, 62] and adults [63] with CF.
The product of the distance walked during a 6MWT and body mass have been reported to
correlate with aerobic capacity (VO2max) in children with CF [64], thus supporting the use of
this test in clinical settings. Furthermore, the 6MWT was found to be valuable for identifying
patients who might experience oxygen desaturation and physical impairment in daily
activities [65]. For this reason, the 6MWT has been considered more reflective of activities of
daily living than other walk tests [59]. Numerous reference equations of the 6MWT are
available for children [66–69] and adults [70].
The 3MST is a simple test that requires the patient to step at a rate of 30 steps per min on and
off a step with 15 cm (6 inch) of height, during 3 minutes. This test was developed for children
with CF by Balfour-Lynn et al. (1998) [71] based on the original Master two-step exercise test
(1929) [72]. One major advantage of the 3MST is that it does not depend on patient’s motivation,
since the cadence of steps is fixed and determined by a metronome. One limitation concerns
to the fact that, as step height and rate are kept constant, the workload varies between patients
depending on their height and lower limb length [51, 58]. The 3MST has been found to be
repeatable [71] and sensitive to changes in pulmonary function and peripheral oxygen
saturation in children with CF following a course of intravenous antibiotics for acute respira‐
tory exacerbations [73]. This is an important finding since even physiotherapists without access
to a formal exercise laboratory may evaluate the response to an intervention using a simple
field test. When compared to the 6MWT, the 3MST elicited a significantly greater change in
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heart rate and breathlessness in children with CF, along with a comparable [71] or higher [74]
fall in oxygen saturation, suggesting that this test is a more vigorous exercise challenge.
Nevertheless, Narang et al. (2003) showed that, in children with mild disease, important
information such as the exercise-related desaturation that occurs at higher exercise levels may
be missed with this test [75].
While the 6MWT and 3MST may be submaximal tests for patients with mild-to-moderate CF,
the MST allows maximal exercise capacity to be reached [58]. The MST [76] consists of a
validated adaptation of the Incremental Shuttle Walk Test [77], specifically developed for
adults with CF. This adaptation allowed individuals to walk and run at increasing speeds over
15 levels with a maximum speed of 10.2 km/h [76]. Bradley et al. (1999, 2000) studied the
validity, reliability and sensitivity of the MST in adults with CF [76, 78]. When compared to a
laboratory-based treadmill test, they showed that 90% of the variation of directly measured
VO2 peak was explained by the variation in MST performance [76]. Moreover, the MST was
effective in evoking a symptom-limited exercise response (i.e., peak heart rate and peak rating
of perceived dyspnoea) similar to what is found in treadmill tests [76]. Thus, it may be a valid
alternative when laboratory-based exercise testing cannot be performed. The validity of the
MST has also been assessed in children with CF (correlation of the MST distance with VO2peak,
r=0.663 p<0.01) [79]. In adults with CF, the MST was found to be reliable (correlation between
trials for distance completed and symptoms reported, r=0.99, p<0.01) and repeatable (coeffi‐
cients of repeatability: distance completed, four shuttles; peak heart rate, 6 beats/min; peak
oxygen saturation, 4%) [78]. The sensitivity of the test was assessed by measuring the change
in MST performance after 2 weeks of antibiotic therapy in patients admitted to hospital with
acute respiratory exacerbations. An effect size of 1.18 was achieved, suggesting that this is a
highly sensitive measure [78]. This test has also been used to assess changes in exercise capacity
after 2 months of exercise training and significant differences were found (median number of
shuttles: from 100 (range 21–150) to 105 (44–150)) [80]. Despite the good measurement
properties, it was recently argued that the 15-level MST developed by Bradley et al. (1999) [76]
still remained sub-maximal for some patients with CF and, thus, levels were extended to 25 in
order to create a truly maximal test [81].
There is no “best” exercise test. The selection of the test will depend upon the aspect of exercise
capacity of interest, availability of resources (i.e., time to perform the test, staff and equipment)
and patient’s characteristics (e.g., age, disease stage) [50, 51]. For example, if the aetiology of
a patient’s reduced exercise capacity is of interest, a laboratory-based test would be more
appropriate, while a field test could be used in large population studies. In addition, a young
child (< 7 years old) may not be able to cooperate sufficiently for a formal laboratory exercise
testing. Physiotherapists have the important role of selecting the best exercise test for a specific
individual according to the specific question being asked and the specificities of each test.
2.1.8. Health-related quality of life
Health-related quality of life (HRQoL) has been extensively studied in patients with CF,
especially in the last decades due to the improvement in patients’ life expectancy [82]. Several
instruments have been used to assess HRQoL in CF, either generic [83-85] or disease-specific
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[85-87]. One disadvantage of generic questionnaires is that they lack the sensitivity needed to
assess areas of functioning that are critically important for patients with CF [88]. Disease-
specific questionnaires were developed in an attempt to better understand CF specific issues
in clinical practice and research.
The most commonly used disease-specific questionnaires include the Cystic Fibrosis Ques‐
tionnaire (CFQ) and the Cystic Fibrosis Quality of Life questionnaire. The CFQ was developed
for assessing HRQoL of patients with CF and encompasses general domains of HRQoL
(physical functioning, role functioning, vitality, health perceptions, emotional functioning and
social functioning), as well as domains specific to CF (body image, eating disturbances,
treatment burden, and respiratory and digestive symptoms) [89]. Three versions of the
instrument have been developed: one for adolescents aged 14 years or older and adults (CFQ-
Teen/Adult), and two for assessing children 6–13 years old, one to be completed by the child
(CFQ-Child) and the other by parents (CFQ-Parent) [89, 90]. Each version takes around 15
minutes to fill in. The different versions of the CFQ questionnaire have shown good psycho‐
metric properties (validity [88-90], reliability [89, 90], internal consistency [88-90] and respon‐
siveness [90]). Hebestreit et al. (2010) found that patients with CF (n=23) enrolling in strength
and endurance training for 6 months improved their subjective health perception (CFQ
domain) significantly between months 3 and 6 (Cohen’s dz=0.92) [56]. Schmidt et al. (2011)
evaluated a 12-week individually tailored unsupervised aerobic exercise programme in 14
patients with CF and also found significant differences in emotional functioning and treatment
burden domains of the CFQ (Cohen’s dz of 0.29 and 1.03) [91]. Thus, this questionnaire may
be used in clinical practice to assess HRQoL of patients with CF, document the progression of
disease and explore the effects of respiratory physiotherapy interventions.
The Cystic Fibrosis Quality of Life questionnaire was specifically developed for adolescents
(14 years old or older) and adults, presenting good validity (concurrent and discriminate),
internal consistency, test–retest reliability results and responsiveness [92]. One advantage of
this instrument is the inclusion of domains concerning wider impacts of the disease on patient's
lives (e.g., interpersonal relationships, career issues and future concerns), which are not found
in other CF questionnaires. Though, it is not adaptable to children.
In sum, disease-specific instruments present good psychometric properties and seem appro‐
priate for several different applications in patients with CF, such as to identify problems and
intervene on an individual basis, compare different CF groups, or detect changes in patients’
HRQoL as a result of disease progression or interventions.
2.2. Emerging outcome measures
2.2.1. Computerised respiratory sounds
Computerised auscultation consists of recording patient’s respiratory sounds with a digital
stethoscope and automatically analysing and classifying them based on specific signal
characteristics [93]. Computerised auscultation allows to objectively detect, characterise and
identify both normal and adventitious (i.e., crackles and wheezes) respiratory sounds within
the breathing cycle [93].
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To assess computerised respiratory sounds, the patient is positioned in the sitting or supine
position (for long-term assessments) and instructed to breath from his/her mouth. Successive
or simultaneous recordings are taken from the trachea plus six chest locations (i.e., right and
left: anterior, lateral and posterior positions), using a single or a multichannel equipment
(Figures 1 and 2) [94].
Figure 1. Single-channel equipment for computerised respiratory sound analysis.
Figure 2. Multi-channel equipment for computerised respiratory sound analysis.
Seven to ten respiratory cycles at tidal breathing or at a flow of 1 to 1.5 L should be recorded
to ensure the stability of sound and quality of the analysis [94]. Then, the sound is filtered using
a combination of low-pass and high-pass filters in cascade to reduce sound artefacts (e.g.,
muscle, heart sounds and movement frequencies) and specialised algorithms for respiratory
sound detection and analysis are implemented [94].
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A wide range of analysis methods exists and new ones are continuously being proposed.
However, the ones with more evidence are time-frequency analysis, fast Fourier and wavelet
transformations, neural networks, periodogram and auto- regressive models [93, 95-97].
Specifically for patients with CF, a time-frequency wheeze detector has already been validated,
demonstrating high levels of sensitivity (77.2%) and specificity (98.4%) [98]. Nevertheless,
algorithms for the detection of crackles in patients with CF were not found and, thus, further
studies are needed.
The reliability of computerised respiratory sounds has been mainly studied in adults with CF
[99] and children with asthma, pneumonia [100] and bronchiolitis [23]. In adults with CF, one
study assessed the test–retest reliability of two main parameters of crackles (i.e., the initial
defection width and the two cycle duration). The intra-subject reliability of crackle parameters
was found to be ‘good’ to ‘excellent’ (0.76<intraclass correlation coefficients<0.94) with no
systematic bias. The smallest real difference found for the initial defection width was between
0.30 and 0.66 ms, and for the two-cycle duration between 1.57 and 2.42 ms. The reliability of
wheezes has only been assessed in children with bronchiolitis, presenting moderate to good
agreement (0.77<kappa<0.79) [99]. The reliability of computerised respiratory sounds to assess
wheezing in adults and its overall reliability in children with CF is still unexplored.
Due to its simplicity and increasing reliability, computerised respiratory sounds have been
used as outcome measures for pharmacological and respiratory physiotherapy interventions
in children and adult patients with several respiratory diseases, including CF [93]. Marques et
al. (2008) investigated the effect of one single session of respiratory physiotherapy using the
ACBT in 17 adult patients with CF [42]. The initial defection width and two cycle duration of
crackles were analysed. Considering the mean of all participants, no significant differences
were found in the analysed parameters. However, when the individual data of each participant
was considered, significant changes were observed in the initial defection width of 9 patients
(53%) and in the two-cycle duration of 10 participants (59%).
Considering the detection of wheezes and their analysis, one study assessing the sensitivity of
computerised respiratory sounds to defect bronchial hyperactivity in 23 children with CF,
following an induced methacholine challenge, found a sensitivity of 50% and a specificity of
100% [101]. Studies in patients with lower respiratory tract infection, a common form of
exacerbation in CF [102], have shown that computerised respiratory sounds are effective in
detecting changes following pharmacological and respiratory physiotherapy interventions
[93]. Small to large effects were found in the number of crackles (Cohen’s dz: 0.14 to 1.65), peak
frequency (Cohen’s dz: 0.11 to 0.47), two-cycle duration (Cohen’s dz: 0.83 to 0.85) and initial/
largest deflection width (Cohen’s dz: 0.38 to 1.25). Better results have been found in the
detection and characterisation of wheezes, with medium to large effect sizes for the number
and occupation rate of wheezes (Cohen’s dz: 0.34 to 4.30) [93].
One of the disadvantages of computerised respiratory sounds concerns the complexity and
costs associated with the equipment and subsequent sound analysis. Nevertheless, an
emerging body of health and engineer researchers have been gathering efforts to produce more
simple and efficient hardware/software that can be used in clinical practice [101, 103].
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Despite the scarce evidence of computerised respiratory sounds in CF, it seems that this
measure might offer potential to assess the short- and long-term effects of respiratory physi‐
otherapy interventions in these patients. However, more research is still required to determine
the parameters of computerised respiratory sounds (i.e., number, frequency, duration) that are
more sensitive to change after an intervention and to establish the reference values that will
allow physiotherapists to interpret with confidence the results obtained from the computerised
auscultation.
2.2.2. Lung ultrasound
Lung ultrasound (LU) is a simple, non-invasive and radiation-free methodology [104] mainly
used in critical care, emergency medicine, trauma surgery and pulmonary medicine for
diagnostic purposes [105]. However, due to its practical and secure character, which enables
its use as often as required, LU has become an attractive alternative imaging technique for
monitoring patients on whom thoracic computed tomography (CT) cannot be performed on
a routine basis or where chest X-ray presents serious limitations in terms of sensitivity and
specificity [106]. In fact, the international evidence-based guidelines for LU recommend this
technique to monitor aeration changes and the effects of therapy in a number of acute respi‐
ratory diseases, including acute pulmonary edema, acute respiratory distress syndrome, acute
lung injury, community-acquired pneumonia, ventilator-associated pneumonia and recovery
from lavage of alveolar proteinosis (level A) [105].
Usually, LU is performed using a 3–5 MHz convex transducer to visualise deeper lung
structures [107, 108]. A high-frequency 5–12 MHz linear probe is most effective in visualising
the chest wall, pleura and the lung peripheral parenchyma [108]. A complete examination of
the chest requires longitudinal, transversal and oblique-array probes to be placed along the
rib spaces, proceeding from top to bottom in the ventral-dorsal direction, along of 12 regions
of interest (parasternal, medial clavicular, anterior axillary, medial, and posterior right and left
chest walls) [106, 108]. Anterior examination should be performed with the patient in the
supine or semi-lateral position [106] while posterior examination should take place with the
patient seated [107].
LU has shown to be reliable in the diagnosis of several acute respiratory conditions, such as
pneumothorax (sensitivity of 65–100%; specificity of 78–100%) [108-110], including the
diagnosis of this condition in patients with CF (specificity of 100%) [109], interstitial syndrome
(sensitivity and specificity of 94%), lung consolidation (sensitivity of 90 to 95%; specificity of
95%), pleural effusion (sensitivity of 90 to 100%; specificity of 100%) [110] and atelectasis
(sensitivity of 88%; specificity of 89%) [104]. One study assessed the inter-subject reliability of
LU in the detection of atelectasis and reported a very good agreement (kappa=0.90; 95%CI 0.75
to 1) [104]. When compared with other imaging equipment (e.g. chest X-ray and MRI), this
measure showed similar or even better reliability results [104, 107, 110].
No data has been found regarding the use of LU to monitor respiratory physiotherapy
interventions in stable or exacerbated patients with CF. Nevertheless, considering its high
accuracy in detecting signals commonly presented in CF exacerbations, such as atelectasis and
consolidation [111], and its increasing impact in the management of acute respiratory condi‐
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tions [105], it is reasonable to conclude that LU may be a promising measure to monitor the
effectiveness of respiratory physiotherapy in patients with acute exacerbations of CF. Consid‐
ering stable CF, one study used LU to characterise diaphragm thickness as a way to infer about
its muscle mass. The authors reported an excellent inter- and intra-subject agreement (90% and
91%, respectively) and showed that LU was capable of detecting differences between patients
with low and high rates of fat-free mass [112]. From these findings, it can be hypothesised that
LU may also play a role in the assessment of the effectiveness of inspiratory muscle training
and general exercise training programmes in increasing the diaphragm thickness of patients
with stable CF, and thus, its muscle mass. Nevertheless, studies assessing the LU validity,
reliability and responsiveness to change are needed before it can be recommended as an
outcome measure for respiratory physiotherapy interventions.
At this point, there is no evidence to recommend LU as an outcome measure for respiratory
physiotherapy in patients with CF. However, the advantages presented by LU over other
imaging measures and its good performance as a diagnostic tool, should motivate further
investigation on the validity and reliability of this measure to assess respiratory physiotherapy
interventions in this population.
2.2.3. Fat-free mass
Fat free mass (FFM) is the component of body mass that represents muscle mass and protein
stores [113] and it is a critical determinant of maximal exercise capacity [114]. It is known that,
in patients with CF, lower FFM is also associated with lower FEV1 percentage predicted and
more frequent respiratory exacerbations [115, 116]. Maintaining appropriate levels of FFM is
therefore crucial for maintaining the overall functional capacity in patients with CF [114].
The gold standard to assess FFM are the 4-C models, which divide body weight into fat, water
and remaining fat-free dry tissue, with the last item further divided into proteins and minerals.
The 4-C models require measurements of body weight, body water, body volume and bone
mineral [117] and thus several specialised equipment, such as dual-energy X-ray, measures of
air displacement plethysmography (BOD POD) and D2O analysis, are needed. The partial
measures are then pulled together in a predictive equation [118]. Although all devices involved
are valid and reliable (intraclass correlation coefficient>0.99), the improved accuracy of the 4-
C models may be offset by the potential propagation of errors due to the inherent measurement
error of each device used to assess each variable [118]. Also, it appears not to be suitable for
widespread clinical use due to the need for specialised equipment, experienced personnel and
large amount of time. Thus, its main value lies in the quality of its evidence in supporting
treatment approaches, rather than in routine practical application [117, 119].
For application of respiratory physiotherapy clinical practice, 2-C models, which require only
the use of one device, are the most recommended and have shown large correlations with the
4-C models. These are bioelectrical impedance (r>0.79, R2=0.70), CT scans (r>0.83, R2=0.96), MRI
(r>0.91), and specially dual-energy X-ray (r>0.91) [120, 121]. Indirect strategies involving
calculations based on anthropometric measurements, such as skinfold thickness analysis, are
controversial. Measuring FFM by measurement of skinfolds implies that no index of this
component of weight is directly measured, and thus it is based on the assumption that
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measuring fatness reflects lean body mass as well. Therefore, its use has not been recommend‐
ed [117]. Nevertheless, studies that show medium correlations between measurements of
skinfold thickness and 4-C models (R2=0.62) exist [120] and support the usability of this
measure to monitor FFM irrespective of the clinical severity of CF [122].
FFM has been used as an outcome measure in respiratory physiotherapy interventions for
children and adults with CF, mainly for the assessment of different types of exercise training.
In the study of Selvadurai et al. (2002), 66 children with exacerbated CF significantly increased
their FFM after five sessions of exercise training (aerobic or resistance training) or chest
physiotherapy, independently of the protocol applied (Cohen’s dz: 1.65 to 5.22) [123]. Sosa et
al. (2012) did not find improvements in the percentage of FFM of children with stable CF
following an 8-week exercise training protocol (78.1 to 79.4%; Cohen’s dz 0.47) [119], however,
significant differences were reached when a component of inspiratory muscle training was
added (81.6 to 82.6%; Cohen’s dz 0.85) [124]. Gruber et al. (2014) compared the effect of a 6-
week interval exercise training vs. standard exercise training in 43 adults with CF [125].
Significant improvements in FFM were only observed in the standard exercise training group
(41.7 to 43.3 kg; Cohen’s dz 0.29). These four studies, with its medium and large effect sizes,
demonstrated that FFM is an adequate outcome measure to assess the effectiveness of
respiratory physiotherapy or just exercise training protocols in patients with CF.
Despite the limited evidence available, FFM assessed with 2-C or 4-C models appears to be a
valid, reliable and usable measure to assess respiratory physiotherapy interventions in CF.
2.2.4. Inspiratory muscle strength
One of the functions of the muscles is to develop strength. In the specific case of the inspiratory
muscles, strength is usually estimated as pressure [126]. Several techniques have been
described to measure inspiratory muscle strength, however, the maximum static inspiratory
pressure at the mouth (Pimax) is one of the most widely used [126].
The assessment of Pimax requires patients to make a maximum inspiratory (Mueller manoeu‐
vre) effort at or near the residual volume, maintained for at least 1–1.5 seconds. These tests are
volitional and require patient’s full cooperation. For these reasons, this technique is usually
performed by an experienced health professional to assure adequate instruction and encour‐
agement. The manoeuver is repeated until the variation between measures is less than 20%.
Pimax is usually expressed in absolute values (cmH2O) or as a percentage of the predicted
values.
Pimax is a simple, low-cost and well tolerated technique. In addition, through the hand-held
and portable electronic pressure transducers, the technique is easily used by physiotherapists
in a wide range of clinical settings (e.g., primary care, hospital wards, intensive care units).
Another advantage of using this technique is the availability of reference values for healthy
children, adults and the elderly, enabling the interpretation of results [127, 128].
The reliability of this measure is well established in people with non-CF bronchiectasis [129]
and healthy people [130]. In patients with CF, only one study was found assessing the test–
retest reliability of Pimax [131]. Pimax had an excellent coefficient of reliability (89%) and
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intraclass correlation coefficient (0.88) in patients with CF (n=20), in line with the results
obtained in healthy individuals (coefficient of reliability 91%; intraclass correlation coefficient
0.87) [131]. One of the disadvantages of this study is the fact that it was conducted only with
adult patients with CF (22.7±3.4 years old). The reliability of Pimax in children with CF is still
unexplored.
Due to its simplicity and adequate reliability, Pimax has been used as an outcome measure of
inspiratory muscle training programmes. In the study by de Jong et al. (2001), seven patients
with CF improved their Pimax from 105 to 123cmH2O after 6 weeks of inspiratory muscle
training (Cohen’s dz 0.82) [132]. Enright et al. (2004) investigated the effect of an 8-week
inspiratory muscle training with a high (n=9) and low (n=10) training intensity. Large effects
were found using the Pimax, with improvements from 114–134cmH2O to 155–159cmH2O
(Cohen’s dz 1.01 and 1.34) [43]. Amelina et al. (2006), after a 6-week inspiratory muscle training,
found that patients with CF (n=10) had a mean improvement from 77% to 91% of the predicted
Pimax (p=0.023; Cohen’s dz 0.73) [133]. These three studies, with its medium and large effect
sizes, demonstrated that Pimax is an adequate outcome measure to assess the effectiveness of
inspiratory muscle training.
Pimax has also been used as an outcome measure to determine the effectiveness of non-
invasive ventilation during chest physiotherapy [39]. It was found that Pimax was maintained
following ACBT assisted with non-invasive ventilation, resulting in a significant difference
compared with ACBT alone (mean difference from standard treatment 9.04cmH2O, 95%CI 4.25
to 13.83, p=0.006) [39].
Despite the limited evidence available, it seems that physiotherapists can confidently rely
on Pimax to assess the effectiveness of respiratory physiotherapy interventions in patients
with CF.
2.2.5. Inspiratory muscle endurance
Inspiratory muscles, in addition to developing strength, have to be able to sustain muscular
tasks over time – also known as endurance [126]. Inspiratory muscle endurance is a highly
complex ability, which provides insight about the resistance to fatigue of inspiratory muscles
and about the function of the inspiratory pump.
Dyspnoea, one of the primary complaints of patients with CF, has been related to inspiratory
muscle fatigue. In adults with CF (n=18), inspiratory muscle endurance was found to be
strongly correlated with exercise dyspnoea (r=−0.72) and explained 48% of the variability of
this symptom [134]. In patients with advanced CF, the assessment and monitoring of inspir‐
atory muscle endurance may have a greater importance since, in these patients, activities of
daily living may be limited by their ability to sustain ventilation. Therefore, the measure of
inspiratory muscle endurance seems to be useful to evaluate the determinants of dyspnoea
and fatigue in patients with CF.
A number of distinct techniques have been employed to measure endurance of the inspiratory
muscles [126]. In CF, two main techniques have been employed: (i) ventilatory endurance tasks
[43, 112, 131] and (ii) endurance to external loads [132, 134].
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In ventilatory endurance tasks, inspiratory muscle endurance has been measured through the
sustained maximum inspiratory pressure (SMIP). This sustained pressure is determined using
an electronic manometer, with a fixed leak via a 2 mm diameter during the inspiratory
manoeuver, and a specific computer software. The leak sets a maximum flow during the
inspiratory effort and allows continuous measurement of pressure over a full range of lung
volumes, until no further pressure can be generated. During this technique, patients are asked
to take a maximal and sustained inspiratory effort from residual volume to total lung capacity.
SMIP is measured as the area under the pressure–time curve and is generally expressed in
absolute values (pressure–time units) [43, 112, 131].
The coefficient of reliability for measurements of SMIP in CF was previously established as
90% [131]. Albinni et al. (2004) reported that inspiratory muscle endurance, measured by the
SMIP, improved significantly in patients with CF (n=16) after 12 weeks of inspiratory muscle
training (p=0.0002) [135]. Enright et al. (2004) investigated the effect of an 8-week inspiratory
muscle training with a training intensity of either 80% of maximal inspiratory effort (n=9) or
20% of maximal inspiratory effort (n=10) [43]. The SMIP improved significantly in the two
groups (from 654–782 to 808–923 pressure–time units; Cohen’s dz 0.46 and 0.51) [43].
In endurance to external loads, inspiratory muscle endurance has been determined with
incremental loading tests using threshold devices. During these tests, patients have to generate
sufficient inspiratory pressure to open the valve and allow inspiratory flow. The test starts
with an inspiratory load of 20–30% of Pimax for 2 min. The load is then increased every 2 min
in increments of 10% of Pimax. The maximal load is defined by the maximal inspiratory
pressure sustained for 1 or 2 min (Plim), which can be expressed in absolute values and as a
percentage of the Pimax [132, 134].
The reliability of the Plim in CF has not yet been explored. In patients with COPD and in
healthy people, however, it has been demonstrated that the reproducibility of the inspiratory
pressure of the threshold was excellent, with small coefficients of variation in both groups
(<1%) [136]. Future studies should assess the reliability and test–retest reliability of the Plim
in the CF population.
Only one small study was found using Plim as an outcome measure in CF population. In this
study, patients with CF (n=7) were submitted to a 6-week inspiratory muscle training. Plim,
expressed as a percentage of the Pimax, increased significantly from 49% to 66% (Cohen’s dz
1.29) [132]. Using Plim, inspiratory muscle training was also found to have large effect sizes
in patients with COPD (n=16; Cohen’s dz 0.83) [137] and with chronic heart failure (n=16;
Cohen’s dz 1.09) [138]. Further research is needed to assess the sensitivity and responsiveness
of Plim to inspiratory muscle training in patients with CF.
Both SMIP and Plim appear to be adequate outcome measures to assess the effectiveness of
inspiratory muscle training in the inspiratory endurance of patients with CF. Nevertheless,
this evidence emerges from few studies with small sample sizes. More research is needed to
determine the responsiveness of these two outcome measures to inspiratory muscle training,
as well as to other respiratory interventions, such as respiratory retraining.
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2.2.6. Physical activity
Given the clinical implications of regular physical activity in patients’ pulmonary function
[139], exercise tolerance [140] and airway clearance [141], its assessment and monitoring in
patients with CF has also become a topic of great interest in research and clinical practice. An
assessment of physical activity (and inactivity) in the free living environment can be performed
using subjective and objective methods [142, 143], although no gold standard is still available.
Subjective methods rely on the individuals’ self-report through physical activity question‐
naires. These instruments are simple, inexpensive and easy to employ for routine assessment
of patients’ physical activity levels [142]. Examples of questionnaires used in CF include the
Habitual Activity Estimation Scale [144] and the Seven Day Physical Activity Recall [145].
Although the Habitual Activity Estimation Scale has presented good test–retest reliability
results (intraclass correlation coefficients of 0.72) in patients with CF [146], a previous system‐
atic review concluded that these two instruments were not able to generate valid activity data
or provide a valid assessment of aerobic fitness at the individual level [147]. Thus, the use of
these questionnaires for individual assessment and counselling may provide imprecise data.
For these purposes, objective measures are recommended.
Objective measures to assess daily physical activity include heart rate monitoring devices and
motion sensors, such as pedometers, accelerometers and multisensor devices [143, 148]. These
measures have been used in studies involving patients with CF [149-151] and show promising
results in evaluating the impact of respiratory physiotherapy interventions [56, 123]. Given
the small size of the devices, low participant burden and relatively low cost, objective measures
are appropriate for use in research and clinical practice [148]. Heart rate monitoring devices
enable the assessment of patients’ level of exertion since heart rate increases in a linear fashion
with oxygen consumption, especially in moderate to strenuous intensity activities [152]. As
such, these devices have been mostly used as a feedback tool to ensure patients’ compliance
with the intensity recommendations when exercising at home [56, 153]. Regarding motion
sensors, there are a large number of options available that makes the choice of the best device
challenging. Pedometers are designed to measure the number of steps taken by an individual
by detecting vertical movement at the hip or waist. They may be desirable in simpler studies
due to their lower cost and limited data [143]. Furthermore, since pedometers provide
immediate feedback to the user [143], they may be valuable in self-monitoring interventions
delivered to patients with CF. Despite their potential applications, no data is still available
regarding the validity and reliability of pedometers in CF [154]. Still, pedometers have
provided good reliability results in healthy and chronic respiratory diseases except when
walking at slower speeds [155].
Although more expensive than pedometers, accelerometers provide a more detailed analysis
of daily physical activity by capturing the frequency, duration and intensity of physical activity
through the collection of body accelerations during movements [143]. They have also the
advantage of storing the data for several weeks [143]. Multisensor devices combine acceler‐
ometry data with physiologic information collected from other sensors, such as heart rate and
skin temperature, and also have a memory function. The use of accelerometers and multisensor
devices in CF has increased dramatically in recent years [140, 146, 156–158] and this will likely
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
55
continue with the technology advances. The clinimetric properties of these devices in CF are
described in a recent systematic review [154]. The authors found that only one accelerometer
(ActiGraph model 7164) and one multisensor device (BodyMedia SenseWear armband) were
tested. The ActiGraph presented good convergent validity [157, 159], test–retest reliability
(intraclass correlation coefficient of 0.63) and feasibility [146, 157] in adolescent and adult
patients with CF. Discriminate validity [160] and responsiveness [123] were only evaluated in
children with CF. Selvadurai et al (2002), exploring the effects of exercise training in children
with CF admitted to hospital (n=66), found a significant improvement in activity levels after
five sessions of endurance training (8.64%, p<0.001, Cohen’s dz 0.82) or resistance training
(3.81%, p<0.001, Cohen’s dz 0.85) measured by accelerometry [123]. Therefore, accelerometers
may be a useful tool to assess changes in physical activity levels of patients with CF in response
of respiratory physiotherapy interventions. Regarding the SenseWear armband device, its
validity (discriminate, convergent and concurrent) [140, 161] was only determined for adult
patients with CF and no data on reliability and responsiveness exist. Further research is needed
to determine which motion sensors provide the best clinimetric properties in CF in order to
improve physiotherapy assessment. Moreover, as children have typically higher physical
activity levels than adults [162], validation studies should be conducted in children and adults
with CF. Finally, it would be useful to develop specific guidelines for the use (e.g., number of
monitoring days, duration) of these motion sensors in CF, in order to standardise the collection
of activity data and optimise their interpretation.
2.2.7. Burden of treatment
The concept of burden of treatment has been receiving increasing attention in patients with
CF. Burden of treatment is described as the increased demand experienced from performing
self-care activities required to undertake treatment regimens and monitor health outcomes
[163]. Recent evidence demonstrated, however, that from a patient’s perspective, treatment
burden is beyond the workload arising from treatment regimens, being experienced in three
disruption domains: biological (physical side effects), biographical (sense of self) and relational
(impact on valued relationships) [164].
A large observational cohort study explored treatment complexity in patients with CF (n=7252)
over a 3-year period [165]. It may be hypothesised that treatment regimens would be more
complex only among patients with more severe disease. Indeed, in this cohort, the highest
treatment complexity was presented by patients with more severe disease. Nevertheless, over
the 3-year period, the complexity of treatment regimens increased in all age and disease
severity groups. This study showed that the recommended management of CF resulted in high
burden of treatment for patients.
In the specific case of respiratory physiotherapy, vigorous airway clearance and exercise
regimens are recommended for patients with CF [166], which may result in increased burden
of treatment. Burden of treatment, in turn, is associated with non-adherence and poor health
outcomes [158, 163, 167–169]. This is particularly important for physiotherapists since the level
of adherence to exercise and physiotherapy is generally reported to be poor (40–55%) [170,
171], in contrast with moderate to high adherence to nebulised medications, pancreatic
enzymes and antibiotics (65–95%) [170, 172].
Cystic Fibrosis in the Light of New Research56
These levels of adherence suggest that patients with CF make decisions based on the com‐
plexity of recommended therapies they can complete, while fulfilling their responsibilities and
commitments to family and work. As the number of adjunct therapies increase in CF, there
may be a point at which perceived treatment burden outweighs the benefits of new or adjunct
therapies, adversely affecting patient’s adherence. Physiotherapists therefore, need to be
sensitive recognising, understanding and supporting the reduction of burden of treatment, in
order to balance the potential benefits and burdens of physiotherapy interventions and
maximise adherence [158, 173].
The recognition of this concept led to the development of specific instruments for assessing
burden of treatment. Burden of treatment has been incorporated into the CFQ [89]. Specifically,
the burden of treatment domain is comprised of three questions: ‘to what extent do your
treatments make your daily life more difficult?’, ‘how much time do you currently spend each
day on your treatments?’ and ‘how difficult is it for you to do your treatments each day?’. The
score ranges from 0 to 100, with lower scores representing higher burden of treatment.
The burden of treatment domain of the CFQ has been used in recent studies evaluating the
effectiveness of novel interventions [91, 174]. In a trial with patients with CF (n=12), assessing
the effect of a nebulised hypertonic saline therapy, a significant improvement was found in
respiratory symptoms together with an increased in perceived burden of treatment (Cohen’s
dz 3.05) [174]. Schmidt et al. (2011) evaluated a 12-week individually tailored unsupervised
aerobic exercise programme in patients with CF (n=14) [91]. Patients were instructed to exercise
at least 30 minutes, three times a week with a heart rate target above 70% of their maximum.
This study showed that an exercise programme could significantly increase VO2max and, at
same time, significantly decrease the perceived burden of treatment (Cohen’s dz 1.03) [91].
These two studies, despite being distinct, show that the burden of treatment domain of the
CFQ is sensitive to change over time and demonstrate large effect sizes. Physiotherapists can,
therefore, confidently rely on the burden of treatment domain of the CFQ to assess their
interventions.
One of the disadvantages of the burden of treatment domain is the fact that it mainly addresses
the complexity and time consuming routine of self-care. However, recent research has
demonstrated that burden of treatment goes beyond these aspects and is experienced as
biological, biographical and relational disruptions [164]. Therefore, when designing future
instruments and methods for assessing burden of treatment, these three disruption domains
should also be taken into account. This highlights the relevance of assessing burden of
treatment as an outcome measure of respiratory physiotherapy in CF. The evaluation of burden
of treatment will also inform the development of new and minimally disruptive interventions.
3. Conclusions
This chapter presented and discussed the strength and weaknesses of the outcome measures
currently applied or emerging in CF respiratory physiotherapy interventions. It provided a
comprehensive overview of the most commonly used, and also addressed the less used and
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some even emerging, outcome measures, which show potential to overcome some of the
barriers to build an evidence base for respiratory physiotherapy practice in patients with CF.
The chapter presented outcome measures possibly to be applied (i) in clinical practice before,
during and after each session of respiratory physiotherapy to monitor its effectiveness; (ii)
before and after the respiratory physiotherapy treatment (i.e., normally characterised by weeks
of intervention) and (iii) clinically, but which main interest is fundamental and/or applied
research in CF respiratory physiotherapy.
In a time where the relationship between “best care” versus “burden of treatment” is discussed,
two factors seem crucial for respiratory physiotherapy: (1) to take into consideration family
and patient’s preferences when providing treatments and (2) build a sound evidence base. For
the latter, a shift of the commonly used outcome measures, namely FEV1, is essential, and a
strong consideration to start applying new outcome measures is recommended.
Author details
Alda Marques1,2*, Joana Cruz1,2, Cristina Jácome1,2 and Ana Oliveira1,2
*Address all correspondence to: amarques@ua.pt
1 Lab 3R - Respiratory Rehabilitation Research Laboratory, School of Health Sciences, Uni‐
versity of Aveiro (ESSUA), Aveiro, Portugal
2 Center for Health Technology and Services Research (CINTESIS), School of Health Sciences,
University of Aveiro, Aveiro, Portugal
References
[1] McIlwaine MP, Lee Son NM, Richmond ML. Physiotherapy and cystic fibrosis: what
is the evidence base? Curr Opin Pulm Med. 2014;20(6):613–7.
[2] Holland AE, Button BM. Physiotherapy for cystic fibrosis in Australia: knowledge
and acceptance of the Consensus Statement recommendations. Respirology.
2013;18(4):652–6.
[3] Bradley JM, Moran FM, Stuart Elborn J. Evidence for physical therapies (airway
clearance and physical training) in cystic fibrosis: an overview of five Cochrane sys‐
tematic reviews. Respir Med. 2006;100(2):191–201.
[4] Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, et al. Guidelines for
the physiotherapy management of the adult, medical, spontaneously breathing pa‐
tient. Thorax. 2009;64(Suppl 1):i1–i52.
Cystic Fibrosis in the Light of New Research58
[5] Main E. Airway clearance research in CF: the 'perfect storm' of strong preference and
effortful participation in long-term, non-blinded studies. Thorax. 2013;68(8):701–2.
[6] Cox NS, Alison JA, Holland AE. Interventions for promoting physical activity in peo‐
ple with cystic fibrosis. Cochrane Database Syst Rev. 2013;12:CD009448.
[7] Warnock L, Gates A, van der Schans CP. Chest physiotherapy compared to no chest
physiotherapy for cystic fibrosis. Cochrane Database Syst Rev. 2013;9:CD001401.
[8] Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standard‐
isation of spirometry. Eur Respir J. 2005;26(2):319–38.
[9] Pfleger A, Theissl B, Oberwaldner B, Zach MS. Self-administered chest physiothera‐
py in cystic fibrosis: a comparative study of high-pressure PEP and autogenic drain‐
age. Lung. 1992;170(6):323–30.
[10] Jarad NA, Powell T, Smith E. Evaluation of a novel sputum clearance technique – hy‐
dro-acoustic therapy (HAT) in adult patients with cystic fibrosis: a feasibility study.
Chron Respir Dis. 2010;7(4):217–27.
[11] Main E, Prasad A, Schans C. Conventional chest physiotherapy compared to other
airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev.
2005(1):Cd002011.
[12] McKoy NA, Saldanha IJ, Odelola OA, Robinson KA. Active cycle of breathing techni‐
que for cystic fibrosis. Cochrane Database Syst Rev. 2012;12:Cd007862.
[13] Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic
fibrosis. Cochrane Database Syst Rev. 2009(1):Cd006842.
[14] Xavier GN, Duarte ACM, Melo-Silva CA, dos Santos CEVG, Amado VM. Accuracy
of pulmonary auscultation to detect abnormal respiratory mechanics: A cross-sec‐
tional diagnostic study. Med Hypotheses. 2014;83(6):733–4.
[15] Abbas A, Fahim A. An automated computerized auscultation and diagnostic system
for pulmonary diseases. J Med Syst. 2010;34(6):1149–55.
[16] Bohadana A, Izbicki G, Kraman SS. Fundamentals of lung auscultation. N Engl J
Med. 2014;370(8):744–51.
[17] Sovijärvi ARA, Vanderschoot J, Earis JE. Standardization of computerized respirato‐
ry sound analysis. Eur Respir Rev. 2000;10(77):974–87.
[18] Marques A, Bruton A, Barney A. Clinically useful outcome measures for physiother‐
apy airway clearance techniques: a review. Physi Ther Rev. 2006;11(4):299–307.
[19] Brooks D, Wilson L, Kelsey C. Accuracy and reliability of 'specialized' physical thera‐
pists in auscultating tape-recorded lung sounds. Physiother Can. 1993;45(1):21–4.
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
59
[20] Allingame S, Williams T, Jenkins S, Tucker B. Accuracy and reliability of physio‐
therapists in the interpretation of tape-recorded lung sounds. Aust J Physiother.
1995;41(3):179–84.
[21] Brooks D, Thomas J. Interrater reliability of auscultation of breath sounds among
physical therapists. Phys Ther. 1995;75(12):1082–8.
[22] Marques A, Oliveira A, Jácome C, Dinis J, Pinho C. 236 Agreement between real-time
auscultation and computerised respiratory analyses. J Cyst Fibros.12:S108.
[23] Elphick HE, Lancaster GA, Solis A, Majumdar A, Gupta R, Smyth RL. Validity and
reliability of acoustic analysis of respiratory sounds in infants. Arch Dis Child.
2004;89(11):1059–63.
[24] Morrow B, Angus L, Greenhough D, Hansen A, McGregor G, Olivier O, et al. The
reliability of identifying bronchial breathing by auscultation. International Journal of
Therapy and Rehabilitation. 2010;17(2):69–75.
[25] Puder LC, Fischer HS, Wilitzki S, Usemann J, Godfrey S, Schmalisch G. Validation of
computerized wheeze detection in young infants during the first months of life. BMC
Pediatr. 2014;14:257.
[26] Tourtier JP, Libert N, Clapson P, Tazarourte K, Borne M, Grasser L, et al. Ausculta‐
tion in flight: comparison of conventional and electronic stethoscopes. Air Med J.
2011;30(3):158–60.
[27] Hoffmann C, Falzone E, Verret C, Pasquier P, Leclerc T, Donat N, et al. Brief report:
pulmonary auscultation in the operating room: a prospective randomized blinded
trial comparing electronic and conventional stethoscopes. Anesth Analg. 2013;117(3):
646–8.
[28] Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, et al.
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: op‐
portunities and challenges to therapy. J Cyst Fibros. 2010;9(1):1–16.
[29] Falk M, Kelstrup M, Andersen JB, Kinoshita T, Falk P, Stovring S, et al. Improving
the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis.
Eur J Respir Dis. 1984;65(6):423–32.
[30] Mortensen J, Falk M, Groth S, Jensen C. The effects of postural drainage and positive
expiratory pressure physiotherapy on tracheobronchial clearance in cystic fibrosis.
Chest. 1991;100(5):1350–7.
[31] Rossman CM, Waldes R, Sampson D, Newhouse MT. Effect of chest physiotherapy
on the removal of mucus in patients with cystic fibrosis. Am Rev Respir Dis.
1982;126(1):131–5.
Cystic Fibrosis in the Light of New Research60
[32] Osman LP, Roughton M, Hodson ME, Pryor JA. Short-term comparative study of
high frequency chest wall oscillation and European airway clearance techniques in
patients with cystic fibrosis. Thorax. 2010;65(3):196–200.
[33] Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. Short-term effects
of three chest physiotherapy regimens in patients hospitalized for pulmonary exacer‐
bations of cystic fibrosis: a cross-over randomized study. Pediatr Pulmonol.
1995;19(1):16–22.
[34] Kluft J, Beker L, Castagnino M, Gaiser J, Chaney H, Fink RJ. A comparison of bron‐
chial drainage treatments in cystic fibrosis. Pediatr Pulmonol. 1996;22(4):271–4.
[35] Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso FJ, Castile RG. Compari‐
son of high-frequency chest wall oscillation and oscillating positive expiratory pres‐
sure in the home management of cystic fibrosis: a pilot study. Pediatr Pulmonol.
2001;32(5):372–7.
[36] Pryor JA, Tannenbaum E, Scott SF, Burgess J, Cramer D, Gyi K, et al. Beyond postur‐
al drainage and percussion: Airway clearance in people with cystic fibrosis. J Cyst Fi‐
bros. 2010;9(3):187–92.
[37] Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst
Rev. 2013;7:CD003884.
[38] Chan ED, Chan MM, Chan MM. Pulse oximetry: understanding its basic principles
facilitates appreciation of its limitations. Respir Med. 2013;107(6):789–99.
[39] Holland AE, Denehy L, Ntoumenopoulos G, Naughton MT, Wilson JW. Non-inva‐
sive ventilation assists chest physiotherapy in adults with acute exacerbations of
cystic fibrosis. Thorax. 2003;58(10):880–4.
[40] Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et
al. An official American Thoracic Society statement: update on the mechanisms, as‐
sessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–
52.
[41] Stenekes SJ, Hughes A, Gregoire MC, Frager G, Robinson WM, McGrath PJ. Frequen‐
cy and self-management of pain, dyspnea, and cough in cystic fibrosis. J Pain Symp‐
tom Manage. 2009;38(6):837–48.
[42] Marques A. The use of computer aided lung sound analysis to characterise adventi‐
tious lung sounds: a potential outcome measure for respiratory therapy. Southamp‐
ton: University of Southampton; 2008.
[43] Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ. Inspiratory muscle train‐
ing improves lung function and exercise capacity in adults with cystic fibrosis. Chest.
2004;126(2):405–11.
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
61
[44] Bausewein C, Booth S, Higginson IJ. Measurement of dyspnoea in the clinical rather
than the research setting. Curr Opin Support Palliat Care. 2008;2(2):95–9.
[45] Neuman MI, Lee EY, Bixby S, Diperna S, Hellinger J, Markowitz R, et al. Variability
in the interpretation of chest radiographs for the diagnosis of pneumonia in children.
J Hosp Med. 2012;7(4):294–8.
[46] McIlwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of
conventional postural drainage and percussion versus positive expiratory pressure
physiotherapy in the treatment of cystic fibrosis. J Pediatr. 1997;131(4):570–4.
[47] McIlwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of
positive expiratory pressure versus oscillating positive expiratory pressure (flutter)
physiotherapy in the treatment of cystic fibrosis. J Pediatr. 2001;138(6):845–50.
[48] Clinical exercise testing with reference to lung diseases: indications, standardization
and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise
Testing. European Respiratory Society. Eur Respir J. 1997;10(11):2662–89.
[49] ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care
Med. 2003;167(2):211–77.
[50] Orenstein DM. Exercise testing in cystic fibrosis. Pediatr Pulmonol. 1998;25(4):223–5.
[51] Rogers D, Prasad SA, Doull I. Exercise testing in children with cystic fibrosis. J R Soc
Med. 2003;96(Suppl 43):23–9.
[52] Palange P, Ward SA, Carlsen K-H, Casaburi R, Gallagher CG, Gosselink R, et al. Rec‐
ommendations on the use of exercise testing in clinical practice. Eur Respir J.
2007;29(1):185–209.
[53] Godfrey S, Mearns M. Pulmonary function and response to exercise in cystic fibrosis.
Arch Dis Child. 1971;46(246):144–51.
[54] McKone EF, Barry SC, FitzGerald MX, Gallagher CG. Reproducibility of maximal ex‐
ercise ergometer testing in patients with cystic fibrosis. Chest. 1999;116(2):363–8.
[55] Saynor ZL, Barker AR, Oades PJ, Williams CA. Reproducibility of maximal cardio‐
pulmonary exercise testing for young cystic fibrosis patients. J Cyst Fibros.
2013;12(6):644–50.
[56] Hebestreit H, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, et al. Long-
term effects of a partially supervised conditioning programme in cystic fibrosis. Eur
Respir J. 2010;35(3):578–83.
[57] Stevens D, Oades PJ, Armstrong N, Williams CA. A survey of exercise testing and
training in UK cystic fibrosis clinics. J Cyst Fibros. 2010;9(5):302–6.
[58] Urquhart D. Exercise testing in cystic fibrosis: why (and how)? J R Soc Med.
2011;104(suppl 1):S6–S14.
Cystic Fibrosis in the Light of New Research62
[59] Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the
measurement properties of functional walk tests used in the cardiorespiratory do‐
main. Chest. 2001;119(1):256–70.
[60] ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med.
2002;166(1):111–7.
[61] Gulmans VAM, van Veldhoven NHMJ, de Meer K, Helders PJM. The six-minute
walking test in children with cystic fibrosis: reliability and validity. Pediatr Pulmo‐
nol. 1996;22(2):85–9.
[62] Cunha MT, Rozov T, de Oliveira RC, Jardim JR. Six-minute walk test in children and
adolescents with cystic fibrosis. Pediatr Pulmonol. 2006;41(7):618–22.
[63] Gruet M, Brisswalter J, Mely L, Vallier J-M. Use of the peak heart rate reached during
six-minute walk test to predict individualized training intensity in patients with cyst‐
ic fibrosis: validity and reliability. Arch Phys Med Rehabil. 2010;91(4):602–7.
[64] Lesser DJ, Fleming MM, Maher CA, Kim SB, Woo MS, Keens TG. Does the 6-min
walk test correlate with the exercise stress test in children? Pediatr Pulmonol.
2010;45(2):135–40.
[65] Ziegler B, Rovedder PM, Lukrafka JL, Oliveira CL, Menna-Barreto SS, Dalcin Pde T.
Submaximal exercise capacity in adolescent and adult patients with cystic fibrosis. J
Bras Pneumol. 2007;33(3):263–9.
[66] Priesnitz CV, Rodrigues GH, da Silva Stumpf C, Viapiana G, Cabral CP, Stein RT, et
al. Reference values for the 6-min walk test in healthy children aged 6–12 years. Pe‐
diatr Pulmonol. 2009;44(12):1174–9.
[67] Klepper SE, Muir N. Reference values on the 6-minute walk test for children living in
the United States. Pediatr Phys Ther. 2011;23(1):32–40.
[68] Kanburoglu MK, Ozdemir FM, Ozkan S, Tunaoglu FS. Reference values of the 6-mi‐
nute walk test in healthy turkish children and adolescents between 11 and 18 years of
age. Respir Care. 2014;59(9):1369–75.
[69] Ulrich S, Hildenbrand F, Treder U, Fischler M, Keusch S, Speich R, et al. Reference
values for the 6-minute walk test in healthy children and adolescents in Switzerland.
BMC Pulm Med. 2013;13(1):49.
[70] Dourado VZ. Equações de referência para o teste de caminhada de seis minutos em
indivíduos saudáveis. Arq Bras Cardiol. 2011;96:e128–e38.
[71] Balfour-Lynn IM, Prasad SA, Laverty A, Whitehead BF, Dinwiddie R. A step in the
right direction: assessing exercise tolerance in cystic fibrosis. Pediatr Pulmonol.
1998;25(4):278–84.
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
63
[72] Master AM, Oppenheimer ET. A simple exercise tolerance test for circulatory effi‐
ciency with standard tables for normal individuals. Am J Med Sci. 1929;177(2):223–
43.
[73] Pike SE, Prasad SA, Balfour-Lynn IM. Effect of intravenous antibiotics on exercise
tolerance (3-min step test) in cystic fibrosis*. Pediatr Pulmonol. 2001;32(1):38–43.
[74] Aurora P, Prasad SA, Balfour-Lynn IM, Slade G, Whitehead B, Dinwiddie R. Exercise
tolerance in children with cystic fibrosis undergoing lung transplantation assess‐
ment. Eur Respir J. 2001;18(2):293–7.
[75] Narang I, Pike S, Rosenthal M, Balfour-Lynn IM, Bush A. Three-minute step test to
assess exercise capacity in children with cystic fibrosis with mild lung disease. Pe‐
diatr Pulmonol. 2003;35(2):108–13.
[76] Bradley J, Howard J, Wallace E, Elborn S. Validity of a modified shuttle test in adult
cystic fibrosis. Thorax. 1999;54(5):437–9.
[77] Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle
walking test of disability in patients with chronic airways obstruction. Thorax.
1992;47(12):1019–24.
[78] Bradley J, Howard J, Wallace E, Elborn S. Reliability, repeatability, and sensitivity of
the modified shuttle test in adult cystic fibrosis. Chest. 2000;117(6):1666–71.
[79] Rogers D, Smith P, John N, Oliver W, IJM D. Validity of a modified shuttle walk test
as a measure of exercise tolerance in paediatric CF patients. J Cys Fibros.
2002;1(Suppl 11):139.
[80] Paranjape SM, Barnes LA, Carson KA, von Berg K, Loosen H, Mogayzel Jr PJ. Exer‐
cise improves lung function and habitual activity in children with cystic fibrosis. J
Cyst Fibros. 2012;11(1):18–23.
[81] Elkins MR, Dentice RL, Bye PT. Validation of the MST-25: an extension of the modi‐
fied shuttle test (MST). J Cyst Fibros. 2009;8, Supplement 2(0):S70.
[82] Royce FH, Carl JC. Health-related quality of life in cystic fibrosis. Curr Opin Pediatr.
2011;23(5):535–40.
[83] Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of
recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.
Chest. 2002;121(1):64–72.
[84] Congleton J, Hodson ME, Duncan-Skingle F. Quality of life in adults with cystic fib‐
rosis. Thorax. 1996;51(9):936–40.
[85] Thomas C, Mitchell P, O'Rourke P, Wainwright C. Quality-of-life in children and
adolescents with cystic fibrosis managed in both regional outreach and cystic fibrosis
center settings in Queensland. J Pediatr. 2006;148(4):508–16.
Cystic Fibrosis in the Light of New Research64
[86] Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Quality of life in cystic fibro‐
sis: the impact of gender, general health perceptions and disease severity. J Cyst Fi‐
bros. 2003;2(4):206–13.
[87] Abbott J, Hart A, Morton A, Gee L, Conway S. Health-related quality of life in adults
with cystic fibrosis: the role of coping. J Psychosom Res. 2008;64(2):149–57.
[88] Modi AC, Quittner AL. Validation of a disease-specific measure of health-related
quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003;28(8):535–46.
[89] Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation
of the cystic fibrosis questionnaire in the United States: A health-related quality-of-
life measure for cystic fibrosis. Chest. 2005;128(4):2347–54.
[90] Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis
Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual
Life Res. 2003;12(1):63–76.
[91] Schmidt AM, Jacobsen U, Bregnballe V, Olesen HV, Ingemann-Hansen T, Thastum
M, et al. Exercise and quality of life in patients with cystic fibrosis: a 12-week inter‐
vention study. Physiother Theory Pract. 2011;27(8):548–56.
[92] Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Development of a disease
specific health related quality of life measure for adults and adolescents with cystic
fibrosis. Thorax. 2000;55(11):946–54.
[93] Marques AS, Oliveira AL, Jacome CI. Computerized adventitious respiratory sounds
as outcome measures for respiratory therapy: a systematic review. Respir Care.
2014;59(5):765–76.
[94] Rossi M, Sovijarvi ARA, Piirila P, Vannuccini L, Dalmasso FVJ. Environmental and
subject conditions and breathing manoeuvres for respiratory sound recordings. Eur
Respir Rev. 2000;10(77):611–5.
[95] Oliveira A, Marques A. Respiratory sounds in healthy people: a systematic review.
Respir Med. 2014;108(4):550–70.
[96] Gurung A, Scrafford CG, Tielsch JM, Levine OS, Check W. Computerized lung
sound analysis as diagnostic aid for the detection of abnormal lung sounds: a system‐
atic review and meta-analysis. Respir Med. 2011;105(9):1396–403.
[97] Reichert S, Gass R, Brandt C, Andres E. Analysis of respiratory sounds: state of the
art. Clinical medicine Circulatory, respiratory and pulmonary medicine. 2008;2:45–
58.
[98] Oliveira D, Pinho C, Marques A, Dinis J. Validation of a time-frequency wheeze de‐
tector in cystic fibrosis: a pilot study. Eur Respir J. 2011;38(55):237s.
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
65
[99] Marques A, Bruton A, Barney A. The reliability of lung crackle characteristics in cyst‐
ic fibrosis and bronchiectasis patients in a clinical setting. Physiol Meas. 2009;30(9):
903–12.
[100] Prodhan P, Dela Rosa RS, Shubina M, Haver KE, Matthews BD, Buck S, et al. Wheeze
detection in the pediatric intensive care unit: comparison among physician, nurses,
respiratory therapists, and a computerized respiratory sound monitor. Respir Care.
2008;53(10):1304–9.
[101] Sanchez I, Powell RE, Pasterkamp H. Wheezing and airflow obstruction during
methacholine challenge in children with cystic fibrosis and in normal children. Am
Rev Respir Dis. 1993;147(3):705–9.
[102] van Ewijk BE, van der Zalm MM, Wolfs TFW, van der Ent CK. Viral respiratory in‐
fections in cystic fibrosis. J Cyst Fibros. 2005;4, Supplement 2(0):31–6.
[103] Pinho C, Oliveira A, Oliveira D, Dinis J, Marques A. Lungsounds@UA Interface and
Multimedia Database. Int J E-Health Med Commun. 2014;5(1):81–95.
[104] Acosta CM, Maidana GA, Jacovitti D, Belaunzaran A, Cereceda S, Rae E, et al. Accu‐
racy of transthoracic lung ultrasound for diagnosing anesthesia-induced atelectasis
in children. Anesthesiology. 2014;120(6):1370–9.
[105] Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, et
al. International evidence-based recommendations for point-of-care lung ultrasound.
Intensive Care Med. 2012;38(4):577–91.
[106] Xirouchaki N, Kondili E, Prinianakis G, Malliotakis P, Georgopoulos D. Impact of
lung ultrasound on clinical decision making in critically ill patients. Intensive Care
Med. 2014;40(1):57–65.
[107] Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, Zechner P, et al. Lung ultra‐
sound in the diagnosis and follow-up of community-acquired pneumonia: a prospec‐
tive, multicenter, diagnostic accuracy study. Chest. 2012;142(4):965–72.
[108] Gardelli G, Feletti F, Nanni A, Mughetti M, Piraccini A, Zompatori M. Chest ultraso‐
nography in the ICU. Respir Care. 2012;57(5):773–81.
[109] Slater A, Goodwin M, Anderson KE, Gleeson FV. COPD can mimic the appearance
of pneumothorax on thoracic ultrasound. Chest. 2006;129(3):545–50.
[110] Xirouchaki N, Magkanas E, Vaporidi K, Kondili E, Plataki M, Patrianakos A, et al.
Lung ultrasound in critically ill patients: comparison with bedside chest radiogra‐
phy. Intensive Care Med. 2011;37(9):1488–93.
[111] Ng MY, Flight W, Smith E. Pulmonary complications of cystic fibrosis. Clin Radiol.
2014;69(3):e153–e62.
Cystic Fibrosis in the Light of New Research66
[112] Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ. The influence of body
composition on respiratory muscle, lung function and diaphragm thickness in adults
with cystic fibrosis. J Cyst Fibros. 2007;6(6):384–90.
[113] Matel JL, Milla CE. Nutrition in cystic fibrosis. Semin Respir Crit Care Med.
2009;30(5):579–86.
[114] Klijn PH, van der Net J, Kimpen JL, Helders PJ, van der Ent CK. Longitudinal deter‐
minants of peak aerobic performance in children with cystic fibrosis. Chest.
2003;124(6):2215–9.
[115] Engelen MP, Schroder R, Van der Hoorn K, Deutz NE, Com G. Use of body mass in‐
dex percentile to identify fat-free mass depletion in children with cystic fibrosis. Clin
Nutr. 2012;31(6):927–33.
[116] Bolton CE, Ionescu AA, Evans WD, Pettit RJ, Shale DJ. Altered tissue distribution in
adults with cystic fibrosis. Thorax. 2003;58(10):885–9.
[117] Wells JC, Fewtrell MS. Measuring body composition. Arch Dis Child. 2006;91(7):612–
7.
[118] Moon JR, Stout JR, Smith-Ryan AE, Kendall KL, Fukuda DH, Cramer JT, et al. Track‐
ing fat-free mass changes in elderly men and women using single-frequency bioim‐
pedance and dual-energy X-ray absorptiometry: a four-compartment model
comparison. Eur J Clin Nutr. 2013;67 Suppl 1:S40–6.
[119] Santana Sosa E, Groeneveld IF, Gonzalez-Saiz L, Lopez-Mojares LM, Villa-Asensi JR,
Barrio Gonzalez MI, et al. Intrahospital weight and aerobic training in children with
cystic fibrosis: a randomized controlled trial. Med Sci Sports Exerc. 2012;44(1):2–11.
[120] Mijnarends DM, Meijers JM, Halfens RJ, ter Borg S, Luiking YC, Verlaan S, et al. Val‐
idity and reliability of tools to measure muscle mass, strength, and physical perform‐
ance in community-dwelling older people: a systematic review. Journal of the
American Medical Directors Association. 2013;14(3):170–8.
[121] Atherton RR, Williams JE, Wells JC, Fewtrell MS. Use of fat mass and fat free mass
standard deviation scores obtained using simple measurement methods in healthy
children and patients: comparison with the reference 4-component model. PLoS
ONE. 2013;8(5):e62139.
[122] de Meer K, Gulmans VA, Westerterp KR, Houwen RH, Berger R. Skinfold measure‐
ments in children with cystic fibrosis: monitoring fat-free mass and exercise effects.
Eur J Pediatr. 1999;158(10):800–6.
[123] Selvadurai HC, Blimkie CJ, Meyers N, Mellis CM, Cooper PJ, Van Asperen PP.
Randomized controlled study of in-hospital exercise training programs in children
with cystic fibrosis. Pediatr Pulmonol. 2002;33(3):194–200.
[124] Santana-Sosa E, Gonzalez-Saiz L, Groeneveld IF, Villa-Asensi JR, Barrio Gómez de
Aguero MI, Fleck SJ, et al. Benefits of combining inspiratory muscle with ‘whole
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
67
muscle’ training in children with cystic fibrosis: a randomised controlled trial. Br J
Sports Med. 2013. Epub: 2013/05/16.
[125] Gruber W, Orenstein DM, Braumann KM, Beneke R. Interval exercise training in
cystic fibrosis – effects on exercise capacity in severely affected adults. J Cyst Fibros.
2014;13(1):86–91.
[126] ATS/ERS Statement on Respiratory Muscle Testing. Am J Respir Crit Care Med.
2002;166(4):518–624.
[127] Enright PL, Kronmal RA, Manolio TA, Schenker MB, Hyatt RE. Respiratory muscle
strength in the elderly. correlates and reference values. Cardiovascular Health Study
Research Group. Am J Respir Crit Care Med. 1994;149(2 Pt 1):430–8.
[128] Wilson SH, Cooke NT, Edwards RH, Spiro SG. Predicted normal values for maximal
respiratory pressures in caucasian adults and children. Thorax. 1984;39(7):535–8.
[129] Moran F, Piper A, Elborn JS, Bradley JM. Respiratory muscle pressures in non-CF
bronchiectasis: repeatability and reliability. Chron Respir Dis. 2010;7(3):165–71.
[130] McConnell AK, Copestake AJ. Maximum static respiratory pressures in healthy eld‐
erly men and women: issues of reproducibility and interpretation. Respiration.
1999;66(3):251–8.
[131] Enright S, Unnithan VB, Davies D. Reproducibility of measurements of inspiratory
work capacity in cystic fibrosis patients. Respir Physiol Neurobiol. 2006;150(1):35–43.
[132] de Jong W, van Aalderen WM, Kraan J, Koeter GH, van der Schans CP. Inspiratory
muscle training in patients with cystic fibrosis. Respir Med. 2001;95(1):31–6.
[133] Amelina E, Cherniak A, Chikina S, Krasovsky S, Appaeva A. Inspiratory muscle
training (IMT) in cystic fibrosis adults. Eur Respir J. 2006:716s.
[134] Leroy S, Perez T, Neviere R, Aguilaniu B, Wallaert B. Determinants of dyspnea and
alveolar hypoventilation during exercise in cystic fibrosis: impact of inspiratory mus‐
cle endurance. J Cyst Fibros. 2011;10(3):159–65.
[135] Albinni S, Rath R, Renner S, Eichler I. Additional inspiratory muscle training intensi‐
fies the beneficial effects of cycle ergonometer training in patients with cystic fibrosis.
J Cyst Fibros. 2004;Suppl1:S63.
[136] Gosselink R, Wagenaar RC, Decramer M. Reliability of a commercially available
threshold loading device in healthy subjects and in patients with chronic obstructive
pulmonary disease. Thorax. 1996;51(6):601–5.
[137] Hill K, Jenkins SC, Philippe DL, Cecins N, Shepherd KL, Green DJ, et al. High-inten‐
sity inspiratory muscle training in COPD. Eur Respir J. 2006;27(6):1119–28.
Cystic Fibrosis in the Light of New Research68
[138] Dall'Ago P, Chiappa GR, Guths H, Stein R, Ribeiro JP. Inspiratory muscle training in
patients with heart failure and inspiratory muscle weakness: a randomized trial. J
Am Coll Cardiol. 2006;47(4):757–63.
[139] Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, et al. Lon‐
gitudinal relationship between physical activity and lung health in patients with
cystic fibrosis. Eur Respir J. 2014;43(3):817–23.
[140] Troosters T, Langer D, Vrijsen B, Segers J, Wouters K, Janssens W, et al. Skeletal mus‐
cle weakness, exercise tolerance and physical activity in adults with cystic fibrosis.
Eur Respir J. 2009;33(1):99–106.
[141] Baldwin DR, Hill AL, Peckham DG, Knox AJ. Effect of addition of exercise to chest
physiotherapy on sputum expectoration and lung function in adults with cystic fib‐
rosis. Respir Med. 1994;88(1):49–53.
[142] Andre D, Wolf DL. Recent advances in free-living physical activity monitoring: a re‐
view. J Diabetes Sci Tech (Online). 2007;1(5):760–7.
[143] Strath SJ, Kaminsky LA, Ainsworth BE, Ekelund U, Freedson PS, Gary RA, et al.
Guide to the Assessment of Physical Activity: Clinical and Research Applications: A
Scientific Statement from the American Heart Association. Circulation. 2013. Epub
2013/10/14.
[144] Hay J, Cairney J. Development of the habitual activity estimation scale for clinical re‐
search: A systematic approach. Pediatric Exercise Science. 2006;18(2):193–202.
[145] Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, et al. Physical ac‐
tivity assessment methodology in the Five-City Project. Am J Epidemiol. 1985;121(1):
91–106.
[146] Wells GD, Wilkes DL, Schneiderman-Walker J, Elmi M, Tullis E, Lands LC, et al. Re‐
liability and validity of the habitual activity estimation scale (HAES) in patients with
cystic fibrosis. Pediatr Pulmonol. 2008;43(4):345–53.
[147] Hulzebos E, Dadema T, Takken T. Measurement of physical activity in patients with
cystic fibrosis: a systematic review. Expert Rev Respir Med. 2013;7(6):647–53.
[148] Trost SG, O'Neil M. Clinical use of objective measures of physical activity. Br J Sports
Med. 2013. Epub 2013/12/05
[149] Aznar S, Gallardo C, Fiuza-Luces C, Santana-Sosa E, López-Mojares LM, Santalla A,
et al. Levels of moderate–vigorous physical activity are low in Spanish children with
cystic fibrosis: A comparison with healthy controls. J Cyst Fibros. 2014;13(3):335–40.
[150] Quon BS, Patrick DL, Edwards TC, Aitken ML, Gibson RL, Genatossio A, et al. Feasi‐
bility of using pedometers to measure daily step counts in cystic fibrosis and an as‐
sessment of its responsiveness to changes in health state. J Cyst Fibros. 2012;11(3):
216–22.
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
69
[151] Ward N, White D, Rowe H, Stiller K, Sullivan T. Physical activity levels of patients
with cystic fibrosis hospitalised with an acute respiratory exacerbation. Respir Med.
2013;107(7):1014–20.
[152] American College of Sports Medicine. ACSM’s resource manual for guidelines for
exercise testing and prescription. 9th ed. Philadelphia: Lippincott Williams & Wil‐
kins; 2014.
[153] Johnson MR, Ferkol TW, Shepherd RW. Energy cost of activity and exercise in chil‐
dren and adolescents with cystic fibrosis. J Cyst Fibros. 2006;5(1):53–8.
[154] Bradley JM, Kent L, Elborn JS, O'Neill B. Motion sensors for monitoring physical ac‐
tivity in cystic fibrosis: what is the next step? Physical Therapy Reviews. 2010;15(3):
197–203.
[155] Turner LJ, Houchen L, Williams J, Singh SJ. Reliability of pedometers to measure step
counts in patients with chronic respiratory disease. J Cardiopulm Rehabil Prev.
2012;32(5):284–91.
[156] Dias A, Gorzelniak L, Jörres RA, Fischer R, Hartvigsen G, Horsch A. Assessing phys‐
ical activity in the daily life of cystic fibrosis patients. Perv Mobile Comput. 2012;8(6):
837–44.
[157] Hebestreit H, Kieser S, Rüdiger S, Schenk T, Junge S, Hebestreit A, et al. Physical ac‐
tivity is independently related to aerobic capacity in cystic fibrosis. Eur Respir J.
2006;28(4):734–9.
[158] Savi D, Quattrucci S, Internullo M, De Biase RV, Calverley PMA, Palange P. Measur‐
ing habitual physical activity in adults with cystic fibrosis. Respir Med. 2013;107(12):
1888–94.
[159] Janz KF, Cassady SL, Barr RN, Kelly JM. Monitoring exercise in children and adoles‐
cents with cystic fibrosis: validation of the CSA accelerometer. Cardiopulm Phys
Ther J. 1995;6(2):3–8.
[160] Selvadurai HC, Blimkie CJ, Cooper PJ, Mellis CM, Van Asperen PP. Gender differen‐
ces in habitual activity in children with cystic fibrosis. Arch Dis Child. 2004;89(10):
928–33.
[161] Dwyer TJ, Alison JA, McKeough ZJ, Elkins MR, Bye PTP. Evaluation of the Sense‐
Wear activity monitor during exercise in cystic fibrosis and in health. Respir Med.
2009;103(10):1511–7.
[162] Troiano RP, Berrigan D, Dodd K, Mâsse L, Tilert T, McDowell M. Physical Activity in
the United States Measured by Accelerometer. Med Sci Sports Exerc. 2008;40(1):181–
8.
Cystic Fibrosis in the Light of New Research70
[163] May C, Eton D, Boehmer K, Gallacher K, Hunt K, MacDonald S, et al. Rethinking the
patient: using burden of treatment theory to understand the changing dynamics of
illness. BMC Health Serv Res. 2014;14(1):281.
[164] Demain S, Goncalves AC, Areia C, Marques A, Marcos AJ, Oliveira R, et al. Living
with and managing treatment burden in long-term conditions: A systematic review
of qualitative research. PLoS Med. 2015;in press.
[165] Sawicki GS, Ren CL, Konstan MW, Millar SJ, Pasta DJ, Quittner AL. Treatment com‐
plexity in cystic fibrosis: trends over time and associations with site-specific out‐
comes. J Cyst Fibros. 2013;12(5):461–7.
[166] Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB,
et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care.
2009;54(4):522–37.
[167] Gallacher K, May CR, Montori VM, Mair FS. Understanding patients’ experiences of
treatment burden in chronic heart failure using normalization process theory. Ann
Fam Med. 2011;9(3):235–43.
[168] Karamanidou C, Weinman J, Horne R. A qualitative study of treatment burden
among haemodialysis recipients. J Health Psychol. 2014;19(4):556–69.
[169] Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, et al.
Building a measurement framework of burden of treatment in complex patients with
chronic conditions: a qualitative study. Patient Rel Outcome Meas. 2012;3:39–49.
[170] Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult
patients with cystic fibrosis. Thorax. 1996;51(1):29–33.
[171] Abbott J, Dodd M, Bilton D, Webb AK. Treatment compliance in adults with cystic
fibrosis. Thorax. 1994;49(2):115–20.
[172] Kettler L, Sawyer S, Winefield H, Greville H. Determinants of adherence in adults
with cystic fibrosis. Thorax. 2002;57(5):459–64.
[173] Jordan S, Philpin S, Warring J, Cheung WY, Williams J. Percutaneous endoscopic
gastrostomies: the burden of treatment from a patient perspective. J Adv Nurs.
2006;56(3):270–-81.
[174] Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus
Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline. N Engl J
Med. 2006;354(3):241–50.
Outcome Measures for Respiratory Physiotherapy in Cystic Fibrosis — Challenges and Advances
http://dx.doi.org/10.5772/60674
71

